Product Information
GNP PAIN RLF PM 250-250-38 MG is a generic product labeled by AmerisourceBergen, priced at $0.0598 per EA under NDC 46122045671. Its NADAC has been published 122 times since Apr 17, 2024.
Strength
250; 250; 38 mg/1; mg/1; mg/1
Manufacturer
AmerisourceBergenNDC
46122045671
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
ACETAMINOPHEN; ASPIRIN; DIPHENHYDRAMINE CITRATEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
8/31/2016
Pharmacological Classes
Price Statistics
The NADAC for GNP PAIN RLF PM 250-250-38 MG has been published 122 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0598 per EA |
|---|---|
| All-time high | $0.0608 (May 15, 2024) |
| All-time low | $0.0538 (Sep 18, 2024) |
| 52-week high | $0.0598 |
| 52-week low | $0.0598 |
| Median price | $0.0598 |
| Average price | $0.0584 |
| Largest weekly change | -4.9% (Aug 21, 2024) |
| Weeks tracked | 122 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
N/A
3M
0.0%
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
-1.6%
Last surveyed Aug 12, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Acetaminophen, Aspirin, Diphenhydramine citrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AmerisourceBergen manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen, Aspirin, Diphenhydramine citrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GNP PAIN RLF PM 250-250-38 MG?
The current National Average Drug Acquisition Cost (NADAC) for GNP PAIN RLF PM 250-250-38 MG, manufactured by AmerisourceBergen, is $0.0598 per EA (NDC 46122045671), effective Aug 12, 2026.
How has the price of GNP PAIN RLF PM 250-250-38 MG changed over time?
Over the history we have for it, the NADAC for GNP PAIN RLF PM 250-250-38 MG has held within roughly two percent of its current level. It has been tracked across 122 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for GNP PAIN RLF PM 250-250-38 MG?
Since Apr 17, 2024, the NADAC for GNP PAIN RLF PM 250-250-38 MG has ranged from a low of $0.0538 (Sep 18, 2024) to a high of $0.0608 (May 15, 2024), with a median of $0.0598 per EA.
Are there cheaper alternatives to GNP PAIN RLF PM 250-250-38 MG?
No other NADAC-published product currently shares the active ingredient and strength of GNP PAIN RLF PM 250-250-38 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GNP PAIN RLF PM 250-250-38 MG?
GNP PAIN RLF PM 250-250-38 MG (NDC 46122045671) is labeled by AmerisourceBergen, and CMS classifies it as a generic product.